All In Biotech

Investigational drug · Phase 2

BS01

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Retinitis Pigmentosa, Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD).

Phase 2

Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

2

Any phase or sponsor naming "BS01"

First trial start

2020

Feb 6, 2020

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "BS01", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Retinitis Pigmentosa
  • Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)

Approved drugs for the same conditions: Wet macular degeneration · Geographic atrophy · Ophthalmology

Largest trials

Live from ClinicalTrials.gov: studies naming "BS01" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 25 on PubMed

Also in development for Retinitis Pigmentosa

  • CPK850Phase 21 trial

    Novartis · Retinitis Pigmentosa

  • famzeretcelhuman retinal progenitor cells, jCellPhase 21 trial

    jCyte, Inc · Retinitis Pigmentosa

  • KIO-301Phase 21 trial

    Kiora Pharmaceuticals, Inc. · Retinitis Pigmentosa

  • OCU400Phase 21 trial

    Ocugen · Retinitis Pigmentosa, Leber Congenital Amaurosis

  • SPVN06Phase 21 trial

    SparingVision · Retinitis Pigmentosa

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.